FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2122406360> ?p ?o ?g. }

• W2122406360 endingPage "728" @default.
• W2122406360 startingPage "716" @default.
• W2122406360 abstract "Patients with advanced basal cell carcinoma have limited treatment options. Hedgehog pathway signalling is aberrantly activated in around 95% of tumours. We assessed the antitumour activity of sonidegib, a Hedgehog signalling inhibitor, in patients with advanced basal cell carcinoma.BOLT is an ongoing multicentre, randomised, double-blind, phase 2 trial. Eligible patients had locally advanced basal cell carcinoma not amenable to curative surgery or radiation or metastatic basal cell carcinoma. Patients were randomised via an automated system in a 1:2 ratio to receive 200 mg or 800 mg oral sonidegib daily, stratified by disease, histological subtype, and geographical region. The primary endpoint was the proportion of patients who achieved an objective response, assessed in the primary efficacy analysis population (patients with fully assessable locally advanced disease and all those with metastatic disease) with data collected up to 6 months after randomisation of the last patient. This trial is registered with ClinicalTrials.gov, number NCT01327053.Between July 20, 2011, and Jan 10, 2013, we enrolled 230 patients, 79 in the 200 mg sonidegib group, and 151 in the 800 mg sonidegib group. Median follow-up was 13·9 months (IQR 10·1-17·3). In the primary efficacy analysis population, 20 (36%, 95% CI 24-50) of 55 patients receiving 200 mg sonidegib and 39 (34%, 25-43) of 116 receiving 800 mg sonidegib achieved an objective response. In the 200 mg sonidegib group, 18 (43%, 95% CI 28-59) patients who achieved an objective response, as assessed by central review, were noted among the 42 with locally advanced basal cell carcinoma and two (15%, 2-45) among the 13 with metastatic disease. In the 800 mg group, 35 (38%, 95% CI 28-48) of 93 patients with locally advanced disease had an objective response, as assessed by central review, as did four (17%, 5-39) of 23 with metastatic disease. Fewer adverse events leading to dose interruptions or reductions (25 [32%] of 79 patients vs 90 [60%] of 150) or treatment discontinuation (17 [22%] vs 54 [36%]) occurred in patients in the 200 mg group than in the 800 mg group. The most common grade 3-4 adverse events were raised creatine kinase (five [6%] in the 200 mg group vs 19 [13%] in the 800 mg group) and lipase concentration (four [5%] vs eight [5%]). Serious adverse events occurred in 11 (14%) of 79 patients in the 200 mg group and 45 (30%) of 150 patients in the 800 mg group.The benefit-to-risk profile of 200 mg sonidegib might offer a new treatment option for patients with advanced basal cell carcinoma, a population that is difficult to treat.Novartis Pharmaceuticals Corporation." @default.
• W2122406360 created "2016-06-24" @default.
• W2122406360 creator A5002280676 @default.
• W2122406360 creator A5007005578 @default.
• W2122406360 creator A5010628808 @default.
• W2122406360 creator A5012911914 @default.
• W2122406360 creator A5014129738 @default.
• W2122406360 creator A5015081105 @default.
• W2122406360 creator A5015624855 @default.
• W2122406360 creator A5022173747 @default.
• W2122406360 creator A5034133629 @default.
• W2122406360 creator A5036648085 @default.
• W2122406360 creator A5037882231 @default.
• W2122406360 creator A5044978994 @default.
• W2122406360 creator A5048419838 @default.
• W2122406360 creator A5048792302 @default.
• W2122406360 creator A5064899437 @default.
• W2122406360 creator A5066544866 @default.
• W2122406360 creator A5077331259 @default.
• W2122406360 creator A5078573167 @default.
• W2122406360 creator A5084705734 @default.
• W2122406360 creator A5085237357 @default.
• W2122406360 creator A5085383984 @default.
• W2122406360 creator A5089297467 @default.
• W2122406360 creator A5090872399 @default.
• W2122406360 date "2015-06-01" @default.
• W2122406360 modified "2023-10-18" @default.
• W2122406360 title "Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial" @default.
• W2122406360 cites W1854220427 @default.
• W2122406360 cites W1978153323 @default.
• W2122406360 cites W1980591242 @default.
• W2122406360 cites W1984999562 @default.
• W2122406360 cites W1990453562 @default.
• W2122406360 cites W1994780310 @default.
• W2122406360 cites W1995143994 @default.
• W2122406360 cites W2019607817 @default.
• W2122406360 cites W2065230160 @default.
• W2122406360 cites W2088811912 @default.
• W2122406360 cites W2101616608 @default.
• W2122406360 cites W2110135410 @default.
• W2122406360 cites W2115116068 @default.
• W2122406360 cites W2117328669 @default.
• W2122406360 cites W2129925282 @default.
• W2122406360 cites W2137271428 @default.
• W2122406360 cites W2139097227 @default.
• W2122406360 cites W2139499843 @default.
• W2122406360 cites W2167571044 @default.
• W2122406360 cites W2169929967 @default.
• W2122406360 cites W2170417775 @default.
• W2122406360 cites W2318044034 @default.
• W2122406360 doi "https://doi.org/10.1016/s1470-2045(15)70100-2" @default.
• W2122406360 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25981810" @default.
• W2122406360 hasPublicationYear "2015" @default.
• W2122406360 type Work @default.
• W2122406360 sameAs 2122406360 @default.
• W2122406360 citedByCount "313" @default.
• W2122406360 countsByYear W21224063602015 @default.
• W2122406360 countsByYear W21224063602016 @default.
• W2122406360 countsByYear W21224063602017 @default.
• W2122406360 countsByYear W21224063602018 @default.
• W2122406360 countsByYear W21224063602019 @default.
• W2122406360 countsByYear W21224063602020 @default.
• W2122406360 countsByYear W21224063602021 @default.
• W2122406360 countsByYear W21224063602022 @default.
• W2122406360 countsByYear W21224063602023 @default.
• W2122406360 crossrefType "journal-article" @default.
• W2122406360 hasAuthorship W2122406360A5002280676 @default.
• W2122406360 hasAuthorship W2122406360A5007005578 @default.
• W2122406360 hasAuthorship W2122406360A5010628808 @default.
• W2122406360 hasAuthorship W2122406360A5012911914 @default.
• W2122406360 hasAuthorship W2122406360A5014129738 @default.
• W2122406360 hasAuthorship W2122406360A5015081105 @default.
• W2122406360 hasAuthorship W2122406360A5015624855 @default.
• W2122406360 hasAuthorship W2122406360A5022173747 @default.
• W2122406360 hasAuthorship W2122406360A5034133629 @default.
• W2122406360 hasAuthorship W2122406360A5036648085 @default.
• W2122406360 hasAuthorship W2122406360A5037882231 @default.
• W2122406360 hasAuthorship W2122406360A5044978994 @default.
• W2122406360 hasAuthorship W2122406360A5048419838 @default.
• W2122406360 hasAuthorship W2122406360A5048792302 @default.
• W2122406360 hasAuthorship W2122406360A5064899437 @default.
• W2122406360 hasAuthorship W2122406360A5066544866 @default.
• W2122406360 hasAuthorship W2122406360A5077331259 @default.
• W2122406360 hasAuthorship W2122406360A5078573167 @default.
• W2122406360 hasAuthorship W2122406360A5084705734 @default.
• W2122406360 hasAuthorship W2122406360A5085237357 @default.
• W2122406360 hasAuthorship W2122406360A5085383984 @default.
• W2122406360 hasAuthorship W2122406360A5089297467 @default.
• W2122406360 hasAuthorship W2122406360A5090872399 @default.
• W2122406360 hasConcept C126322002 @default.
• W2122406360 hasConcept C141071460 @default.
• W2122406360 hasConcept C143998085 @default.
• W2122406360 hasConcept C203092338 @default.
• W2122406360 hasConcept C2777546739 @default.
• W2122406360 hasConcept C2778804307 @default.
• W2122406360 hasConcept C2779545874 @default.
• W2122406360 hasConcept C2779984678 @default.
• W2122406360 hasConcept C2908647359 @default.

• next